COMMUNIQUÉS West-GlobeNewswire

Bellerophon Therapeutics Announces Enrollment Exceeds 100 Patients in Phase 3 INOvation-1 Study Evaluating INOpulse® for Treatment of Pulmonary Arterial Hypertension
29/01/2018
WARREN, N.J., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH ), a clinical-stage biotherapeutics company, today announced that enrollment in its Phase 3 INOvation-1 study evaluating [...]
China Oncology Focus Limited Receives Approval by Chinese Authorities to Begin Clinical Trials in Three Separate Cancer Indications Using Sorrento’s Anti-PD-L1 Monoclonal Antibody
29/01/2018
HONG KONG and SAN DIEGO, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Effective January 29th, 2018, Lee’s Pharm and Sorrento Therapeutics announce that the Chinese authorities have approved China Oncology Focus Limited (COF, an [...]
Rexahn Pharmaceuticals Receives Notice of Allowance for A New U.S. Patent Covering the Use of RX-5902 (Supinoxin™)
29/01/2018
ROCKVILLE, Md., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, [...]
Cidara Therapeutics Announces Presentations at the 8th Advances Against Aspergillosis Conference and 2018 BMT Tandem Meeting
29/01/2018
SAN DIEGO, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX ), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical [...]
PositiveID Corporation Publishes White Paper and Data on its Successful Detection of Influenza Virus
29/01/2018
DELRAY BEACH, Fla., Jan. 29, 2018 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTC:PSID), a life sciences company focused on detection and diagnostics, announced today that it has published a [...]
Pernix Announces Patent Litigation Settlement Agreement with Actavis Concerning Zohydro® ER
29/01/2018
MORRISTOWN, N.J., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX ), a specialty pharmaceutical company, today announced that it has entered into a settlement agreement with Actavis [...]
Cellectar Initiates DLBCL Cohort in Phase 2 Trial of CLR 131 in Refractory B-Cell Hematologic Cancers
29/01/2018
MADISON, Wis., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB ), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment [...]
Evogene to Participate in Israeli Consortium to Develop Phenotyping Tools and Systems for Precision Agriculture
29/01/2018
REHOVOT, Israel, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ: EVGN ) (TASE: EVGN ), a leading biotechnology company developing novel products for life science markets through the use of a unique computational [...]
HempAmericana CEO Issues Letter to Shareholders
29/01/2018
NEW YORK, Jan. 29, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- HempAmericana, Inc. (OTC:HMPQ) (“HempAmericana” or the “Company”) CEO issues the following letter to Shareholders Dear Valued Shareholder, The purpose of [...]
XORTX Therapeutics Announces Appointment of Allan Williams and Paul Van Damme
29/01/2018
CALGARY, Alberta, Jan. 29, 2018 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE:XRX), a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney [...]
Canadian Drug Expert Committee Grants Positive Recommendation for Reimbursement of Galafold™ (migalastat) for Fabry Disease in Canada
29/01/2018
CRANBURY, N.J., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD ) announced that the Common Drug Review (CDR) has posted the Canadian Drug Expert Committee (CDEC)’s positive recommendation of [...]
Alder BioPharmaceuticals, Inc. Announces Offering of $200 Million of Convertible Senior Notes Due 2025
29/01/2018
BOTHELL, Wash., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR ), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced [...]
Faron Pharmaceuticals Oy: FDA grants Fast Track Designation to Faron for Traumakine®
29/01/2018
Faron Pharmaceuticals Ltd ("Faron" or the "Company") FDA grants Fast Track Designation to Faron for Traumakine ® Faron's wholly-owned product for Acute Respiratory Distress Syndrome on track for Phase III data in H1 [...]
Rhizen Pharmaceuticals S.A. announces clinical data presentations for Tenalisib (RP6530) in R/R T-cell lymphoma at the upcoming 10th Annual T-Cell Lymphoma Forum in La Jolla, CA, USA
29/01/2018
La Chaux-de-Fonds, Switzerland, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that updated clinical data for Tenalisib (RP6530), the company’s highly selective and orally active dual [...]
Microbix Featured at Cantech Investment Conference
29/01/2018
TORONTO, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX ) (Microbix ® ), an innovator of biological products and technologies, announces its participation as a panelist and exhibitor at the Cantech [...]
Protalix BioTherapeutics to Participate in the 14th Annual WORLDSymposium™ 2018
29/01/2018
CARMIEL, Israel, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE: PLX ), announced today that the Company will participate in the 14 th Annual WORLD Symposium™ 2018 taking place [...]
Melinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the United States
29/01/2018
– Approved for adult patients with acute bacterial skin and skin structure infections (ABSSSI) – – Provides coverage of gram-positive and gram-negative pathogens; only FDA-approved fluoroquinolone for methicillin- [...]
Athersys CEO to Speak at the 2018 Brain Health Summit
29/01/2018
CLEVELAND, Ohio, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX ) announced today that Gil Van Bokkelen, Chairman and CEO, will be a speaker and panelist at the 2018 Brain Health Summit organized by the [...]
Genetic Technologies Limited: Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the quarter ended 31 December 2017
29/01/2018
HIGHLIGHTS Completed a three month promotional campaign leading up to and throughout October Breast Cancer Awareness Month Ohio State University: patient recruitment for the collaborative clinical research study [...]

Pages